{"prompt": "['Regimen allowed', '5-FU/LV', 'Irinotecan', 'Durvalumab', 'Tremelimumab', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Regimen not allowed', '5-FU/LV', 'Irinotecan', 'Durvalumab', 'Tremelimumab', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '7.3. Dose adjustment based on infusion-related reaction', 'In the event of a VI grade 2 infusion-related reaction, the infusion rate of study drug may be decreased by 50% or', 'interrupted until resolution of the event and re-initiated at 50% of the initial rate until completion of the', 'infusion. For patients with a grade 2 infusion-related reaction, subsequent infusions may be administered at', '50% of the initial rate. Acetaminophen and/or an antihistamine (e.g., diphenhydramine) or equivalent', 'medications per institutional standard may be administered at the discretion of the investigator. If the', 'infusion-related reaction is > grade 3 or higher in severity, study drug will be discontinued. For management of', 'patients who experience an infusion reaction, please refer to the toxicity and management guidelines in', 'Appendix 8.', 'As with any antibody, allergic reactions to dose administration are possible. Appropriate drugs and medical', 'equipment to treat acute anaphylactic reactions must be immediately available, and study personnel must be', 'trained to recognize and treat anaphylaxis. The study site must have immediate access to emergency', 'resuscitation teams and equipment in addition to the ability to admit patients to an intensive care unit if', 'necessary.', '7.4. Dose adjustment of FOLFIRI', 'Please refer to the references to the updated SmPCs for the products used for issues of patient management,', 'particularly with respect to contraindications, warnings and precautions for use, dose adjustment in the event of', 'toxicity, monitoring of patients, duration of contraception and medicinal products that are forbidden or to be', 'used with precautions. The links to updated versions of the SmPCs are provided in Appendix 9 of this protocol.', 'Dose adjustment of FOLFIRI according to the higher hematological toxicity occurring the day of the', 'course. In case of grade 4 or febrile neutropenia, the course must be reported until grade 1.', 'Grade toxicity', '5-FU', 'Irinotecan', '(NCI-CTCAE v4)', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 24 de 123']['Neutropenia,', 'thrombocytopenia', '- Bolus reduction of 50%', '- No modification', 'Grade 2', '- Bolus suppression, reduction of 25% of', '- No modification', 'Grade 3a', 'continuous 5-FU', '- Bolus suppression, reduction of 25% of', '- Reduction of 25%', 'Grade 4b', 'continuous 5-FU', '-', 'Bolus suppression, reduction of 25% of', '- Reduction of 25%', 'Febrile neutropeniab', 'continuous 5-FU', 'a Discuss about G-CSF prescription if persistence of neutropenia < 1500/mm\u00b3 after 1-week postponement', 'b', 'Discuss about G-CSF prescription if Grade 4 neutropenia or febrile neutropenia', 'Dose adjustment of FOLFIRI according to maximal toxicity in the intercourse', 'Grade toxicity', '5-FU', 'Irinotecan', '(NCI-CTCAE v4)', 'Neutropenia,', 'thrombocytopenia', '- No modification', '- No modification', 'Grade 2', '- No modification', '- No modification', 'Grade 3', '- Bolus suppression', '- No modification', 'Grade 4b', '- Bolus suppression, reduction of 25% of', '- Reduction of 25%', 'Febrile neutropeniab', 'continuous 5-FU', 'a', 'Discuss about G-CSF prescription if Grade 4 neutropenia or febrile neutropenia', 'Other toxicities according to maximal toxicity in the intercourse', 'Grade toxicity', '5-FU', 'Irinotecan', '(NCI-CTCAE v4)', 'Diarrhea despite maximum', 'symptomatic treatment', 'Grade 2', '- Bolus reduction of 50%', '- Reduction of 25%', 'Grade 3', '- Bolus suppression, reduction of 50% of', '- Reduction of 25%', 'continuous 5-FU', 'Grade 4', '- Discuss discontinuation of chemotherapy or only', '- Discuss discontinuation of', 'irinotecan if recurrence despite dose reduction', 'chemotherapy if recurrence despite dose', 'reduction', 'Mucositis', 'Grade 2', '- Bolus reduction of 50%', '- No modification', 'Grade 3', '-Bolus suppression, reduction of 25% of', '- No modification', 'continuous 5-FU', 'Grade 4', '- Discuss discontinuation of chemotherapy or only', '- Discuss discontinuation of', 'irinotecan if recurrence despite dose reduction', 'chemotherapy if recurrence despite dose', 'reduction', 'Vomiting', 'Grade 3', '- Reduction of 25% of continuous 5-FU', '- Reduction of 25%', 'Grade 4', '- Discuss discontinuation of chemotherapy or only', '- Discuss discontinuation of', 'irinotecan if recurrence despite dose reduction', 'chemotherapy if recurrence despite dose', 'reduction', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 25 de 123']\n\n###\n\n", "completion": "END"}